Advanced Proteome Therapeutics Stock Annual Yield
| APTCF Stock | USD 0.0002 0.00 0.00% |
Advanced Proteome Therapeutics fundamentals help investors to digest information that contributes to Advanced Proteome's financial success or failures. It also enables traders to predict the movement of Advanced Pink Sheet. The fundamental analysis module provides a way to measure Advanced Proteome's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Advanced Proteome pink sheet.
Advanced |
Advanced Proteome Therapeutics Company Annual Yield Analysis
Advanced Proteome's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Advanced Proteome Therapeutics has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run AI Portfolio Architect Now
AI Portfolio ArchitectUse AI to generate optimal portfolios and find profitable investment opportunities |
| All Next | Launch Module |
Advanced Fundamentals
| Return On Asset | -1.07 | |||
| Current Valuation | 660.53 K | |||
| Shares Outstanding | 41.13 M | |||
| Shares Owned By Insiders | 10.53 % | |||
| Price To Earning | 2.98 X | |||
| Price To Book | 4.92 X | |||
| Gross Profit | (1.71 K) | |||
| EBITDA | 631.22 K | |||
| Net Income | 759.62 K | |||
| Cash And Equivalents | 761.6 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 227.41 K | |||
| Debt To Equity | 4.65 % | |||
| Current Ratio | 0.55 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (693.58 K) | |||
| Earnings Per Share | 0.02 X | |||
| Number Of Employees | 11 | |||
| Beta | 1.55 | |||
| Market Capitalization | 2.47 M | |||
| Total Asset | 636.41 K | |||
| Z Score | 6.0 | |||
| Net Asset | 636.41 K |
About Advanced Proteome Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Advanced Proteome Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Advanced Proteome using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Advanced Proteome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Advanced Pink Sheet
Advanced Proteome financial ratios help investors to determine whether Advanced Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Advanced with respect to the benefits of owning Advanced Proteome security.